| Literature DB >> 22518154 |
Ranji Varghese1, Nathan G Adams, Nancy L Slocumb, Christopher F Viozzi, Kannan Ramar, Eric J Olson.
Abstract
Maxillomandibular advancement (MMA) is a surgical option for obstructive sleep apnea (OSA). MMA involves forward-fixing the maxilla and mandible approximately 10 mm via Le Fort I maxillary and sagittal split mandibular osteotomies. We retrospectively reviewed outcomes from 24 consecutive OSA patients who underwent MMA at our institution. MMA resulted in an 83% reduction in the group mean apnea-hypopnea index (AHI) per polysomnography an average of 6.7 months after surgery. Forty-two percent of patients achieved a post-MMA AHI of less than 5 events/hour sleep and 71% achieved an AHI less than or equal to 10 events/hour sleep. The Epworth Sleepiness Scale score decreased by an average of 5 post-surgery. No parameters predictive of cure for OSA by MMA were identified.Entities:
Year: 2012 PMID: 22518154 PMCID: PMC3299305 DOI: 10.1155/2012/373025
Source DB: PubMed Journal: Int J Otolaryngol ISSN: 1687-9201
Figure 1Pre- (a) and post- (b) maxillomandibular advancement (MMA) lateral cephalometric radiographs demonstrating analyzed parameters. Pre- and post-MMA cephalometric images were digitally overlaid to determine the change in position of the following parameters: anatomic B-point (most posterior midline point in the anterior concavity of the mandible); posterior nasal spine (PNS) along the sella-nasion line; and sella-nasion-point B (SNB) angle. Enlargement of the posterior airway space was also determined on all cephalometric radiographs by measuring the narrowest point in the airway pre- and post-MMA, then subtracting the larger (post-MMA) value from the smaller (pre-MMA) value to obtain the difference.
Group pre- and post-maxillomandibular advancement (MMA) demographic- and polysomnographic-matched pair data.
|
| Pre-MMA | Post MMA |
| |
|---|---|---|---|---|
| ESS | 14 | 13.6 ± 5.4 | 8.8 ± 3.3 | 0.0063** |
| BMI (kg/m2) | 18 | 30.5 ± 6.0 | 30.3 ± 5.3 | 0.7 |
| AHI (number/hour) | 24 | 45.4 ± 26.4 | 7.8 ± 10.5 | <0.0001** |
| Sleep efficiency (%) | 17 | 72.2 ± 18.9 | 78.6 ± 16.7 | 0.2 |
| Stage N1 (%) | 15 | 22.3 ± 15.9 | 14.2 ± 11.2 | 0.08 |
| Stage N2 (%) | 15 | 55.4 ± 12.1 | 55.3 ± 8.3 | 0.97 |
| Stage N3 (%) | 15 | 10.7 ± 10.2 | 15.3 ± 8.3 | 0.04** |
| Stage R (%) | 16 | 9.1 ± 7.2 | 15.2 ± 6.9 | 0.0078** |
| Respiratory-related arousals (events/hour) | 12 | 49.0 ± 21.4 | 11.5 ± 14.9 | 0.0002** |
| Lowest oxyhemoglobin saturation (%) | 21 | 81.2 ± 8.0 | 86.2 ± 5.6 | 0.03** |
| Time in supine position (%) | 12 | 44.4 ± 28.5 | 41.7 ± 28.9 | 0.7 |
Abbreviations: SD: standard deviation; ESS: Epworth Sleepiness Scale; BMI: body mass index (kg/m2); AHI: apnea-hypopnea index (apneas and hypopneas per hour of sleep); N: non-rapid eye movement sleep; R: rapid eye movement sleep.
Selected, patient-specific data on demographics, previous airway surgery, surgical advancement, and sleep-disordered breathing pre- and post-maxillomandibular advancement (MMA).
| Patient | Gender | Pre-MMA upper airway surgery | Age at MMA | Maxillary advancement (mm) | Mandibular advancement (mm) | Pre-MMA AHI | Post-MMA AHI | % AHI reduction |
|---|---|---|---|---|---|---|---|---|
| 1 | F | None | 39 | 8 | 7 | 24 | 1 | 96 |
| 2 | M | None | 45 | NA | NA | 30 | 1 | 97 |
| 3 | F | None | 57 | 9 | 9 | 21 | 11 | 48 |
| 4 | M | UPPP, bilateral tonsillectomy | 48 | 8 | 8 | 37 | 11 | 70 |
| 5 | M | None | 61 | 10 | 3 | 26 | 42 | — |
| 6 | M | UPPP | 36 | 10 | 10 | 80 | 1 | 99 |
| 7 | M | None | 35 | 6 | 6 | 23 | 1 | 96 |
| 8 | M | UPPP, Genioglossus advancement | 33 | 10 | 10 | 38 | 0 | 100 |
| 9 | F | None | 55 | 10 | 10 | 80 | 11 | 86 |
| 10 | M | UPPP, nasal septoplasty | 54 | 10 | 10 | 37 | 1 | 97 |
| 11 | M | None | 55 | 7 | 7 | 8 | 1 | 88 |
| 12 | M | None | 42 | 10 | 10 | 12 | 5 | 58 |
| 13 | M | None | 57 | 8 | 8 | 54 | 5 | 91 |
| 14 | M | None | 49 | 10 | 10 | 52 | 2 | 96 |
| 15 | F | UPPP, nasal septoplasty | 48 | 10 | 10 | 56 | 1 | 98 |
| 16 | M | None | 56 | 10 | 10 | 37 | 9 | 76 |
| 17 | M | None | 45 | 10 | 10 | 25 | 5 | 80 |
| 18 | M | UPPP | 44 | 12 | 12 | 117 | 1 | 99 |
| 19 | M | None | 26 | NA | NA | 33 | 11 | 67 |
| 20 | M | UPPP, nasal septoplasty | 50 | 10 | 10 | 39 | 7 | 82 |
| 21 | F | None | 71 | NA | NA | 53 | 14 | 74 |
| 22 | M | None | 30 | 10 | 10 | 95 | 6 | 94 |
| 23 | F | None | 58 | 10 | 10 | 51 | 36 | 29 |
| 24 | M | Genial advancement | 51 | 10 | 10 | 60 | 5 | 92 |
Abbreviations: F: female; M: male; UPPP: uvulopalatopharyngoplasty; AHI: apnea-hypopnea index (apneas and hypopneas/hour sleep); NA: data not available.
Comparison of parameters between patients cured versus those with residual obstructive sleep apnea following maxillomandibular advancement (MMA).
| Post-MMA | |||||
|---|---|---|---|---|---|
| Surgical cure (AHI < 5) |
| No cure (AHI ≥ 5) |
|
| |
| Pre-MMA | 14 | ||||
| Age (years) | 44.4 ± 7.8 | 10 | 51.0 ± 12.0 | 14 | 0.07 |
| Male (%) | 80 | 8 | 71.4 | 10 | 0.5 |
| BMI | 30.3 ± 4.4 | 9 | 31.0 ± 6.5 | 12 | 0.9 |
| AHI (events/h) | 46.5 ± 31.9 | 10 | 44.6 ± 23.0 | 14 | 0.9 |
| SpO2 nadir (%) | 81.1 ± 9.6 | 10 | 81.3 ± 6.6 | 12 | 0.7 |
| Previous phase-I surgery1 (%) | 62.5 | 5/8 | 37.5 | 3/8 | 0.2 |
|
| |||||
| Surgery | |||||
| Maxillary advancement (mm) | 9.2 ± 1.9 | 9 | 9.6 ± 0.8 | 12 | 0.8 |
| Mandibular advancement (mm) | 9.1 ± 2.0 | 9 | 9.0 ± 2.0 | 12 | 0.9 |
|
| |||||
| Post-MMA | |||||
| BMI (kg/m2) | 29.2 ± 7.1 | 8 | 30.0 ± 3.8 | 13 | 0.9 |
| % Change in BMI (%) | −1.7 ± 5.5 | 7 | 0.5 ± 6.7 | 11 | 0.6 |
| AHI (events/h) | 1.0 ± 0.5 | 10 | 12.7 ± 11.6 | 14 | <0.0001 |
| % Change in AHI (%) | −96.5 ± 3.5 | 10 | −63.2 ± 40.1 | 14 | <0.0001 |
| SpO2 nadir (%) | 88.8 ± 4.2 | 10 | 84.1 ± 5.2 | 14 | 0.0221 |
| % Change in SpO2 nadir (%) | 10.9 ± 14.9 | 10 | 3.9 ± 12.8 | 12 | 0.2 |
Abbreviations: SD: standard deviation; BMI: body mass index (kg/m2); AHI: apnea-hypopnea index (apneas and hypopneas/hour sleep); SpO2: oxyhemoglobin saturation.
1Patients who underwent an upper airway procedure prior to MMA.